ANI Pharmaceuticals (ANIP) In A Perilous Reversal
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Trade-Ideas LLC identified
(
) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified ANI Pharmaceuticals as such a stock due to the following factors:
- ANIP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $32.0 million.
- ANIP has traded 112,577 shares today.
- ANIP is down 3.3% today.
- ANIP was up 7.3% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ANIP with the Ticky from Trade-Ideas. See the FREE profile for ANIP NOW at Trade-Ideas
More details on ANIP:
ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products. ANIP has a PE ratio of 24.3. Currently there are 2 analysts that rate ANI Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for ANI Pharmaceuticals has been 315,900 shares per day over the past 30 days. ANI has a market cap of $716.5 million and is part of the health care sector and drugs industry. The stock has a beta of 3.60 and a short float of 20.5% with 2.88 days to cover. Shares are up 19.7% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates ANI Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good.
Highlights from the ratings report include:
- Compared to other companies in the Pharmaceuticals industry and the overall market, ANI PHARMACEUTICALS INC's return on equity exceeds that of both the industry average and the S&P 500.
- ANIP's very impressive revenue growth greatly exceeded the industry average of 10.3%. Since the same quarter one year prior, revenues leaped by 99.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The debt-to-equity ratio is somewhat low, currently at 0.79, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with this, the company maintains a quick ratio of 14.08, which clearly demonstrates the ability to cover short-term cash needs.
- The gross profit margin for ANI PHARMACEUTICALS INC is currently very high, coming in at 82.54%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 99.84% significantly outperformed against the industry average.
- Net operating cash flow has significantly increased by 474.90% to $10.74 million when compared to the same quarter last year. In addition, ANI PHARMACEUTICALS INC has also vastly surpassed the industry average cash flow growth rate of -9.86%.
- You can view the full ANI Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null